CNS Pharmaceuticals, Inc. (CNSP)

NASDAQ: CNSP · IEX Real-Time Price · USD
2.16
-0.19 (-7.89%)
At close: Feb 7, 2023, 4:00 PM
2.22
+0.06 (2.78%)
After-hours: Feb 7, 2023, 7:28 PM EST
-7.89%
Market Cap 2.88M
Revenue (ttm) n/a
Net Income (ttm) -12.56M
Shares Out 1.33M
EPS (ttm) -10.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 76,471
Open 2.31
Previous Close 2.35
Day's Range 2.12 - 2.43
52-Week Range 2.05 - 16.50
Beta 1.18
Analysts Sell
Price Target 10.20 (+372.22%)
Earnings Date Mar 2, 2023

About CNSP

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceu... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 8, 2019
Employees 3
Stock Exchange NASDAQ
Ticker Symbol CNSP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for CNSP stock is "Sell." The 12-month stock price forecast is $10.2, which is an increase of 372.22% from the latest price.

Price Target
$10.2
(372.22% upside)
Analyst Consensus: Sell
Stock Forecasts

News

CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

Enrollment continuing to progress toward an interim analysis, planned when 30-50% of subjects reach the primary endpoint expected mid-year 2023 HOUSTON , Feb. 7, 2023 /PRNewswire/ --  CNS Pharmaceutic...

18 hours ago - PRNewsWire

CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in Poland

Study to evaluate Berubicin for the treatment of newly diagnosed and relapsed/refractory primary central nervous system lymphoma (PCNSL) or non-Hodgkin's lymphoma with central nervous system involveme...

3 weeks ago - PRNewsWire

CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event

Live video webcast on Wednesday, January 18 th at 10:00 AM ET   HOUSTON , January 5, 2023 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company...

1 month ago - PRNewsWire

CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of Directors

Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations HOUSTON , Jan. 3, 2023 /PRNewswi...

1 month ago - PRNewsWire

CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)

Data recently presented at the Society for Neuro-Oncology (SNO) 27th Annual Meeting Preliminary results showcase updated patient population profile and safety Continued progress toward planned interim...

2 months ago - PRNewsWire

CNS Pharmaceuticals to Participate at the Virtual Investor "Ask the CEO" Event

Live moderated video webcast event intended to provide the investment community direct access to ask their questions to John Climaco, Chief Executive Officer on Tuesday, December 6 th at 11:00 AM ET H...

2 months ago - PRNewsWire

CNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing Price

HOUSTON , Nov. 30, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary a...

2 months ago - PRNewsWire

CNS Pharmaceuticals Announces Reverse Stock Split

HOUSTON , Nov. 28, 2022 /PRNewswire/ --  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary ...

2 months ago - PRNewsWire

CNS Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Significant progress advancing potentially pivotal trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM) Quarter marked by expansion into Europe with multiple clinica...

3 months ago - PRNewsWire

CNS Pharmaceuticals Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

Enrollment progressing toward interim analysis, planned when 30-50% of subjects reach 6 months in study HOUSTON , Nov. 2, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "C...

3 months ago - PRNewsWire

CNS Pharmaceuticals to Participate in The American Brain Tumor Association's Breakthrough (ABTA) for Brain Tumors® 5K (BT5K) Run

HOUSTON , Oct. 10, 2022 /PRNewswire/ --  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary ...

4 months ago - PRNewsWire

CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Activation of First Clinical Trial Sites in Europe Evaluating Berubicin for the Treatment of GBM

LOS ANGELES, Oct. 07, 2022 (GLOBE NEWSWIRE) -- InvestorWire -- CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments for p...

4 months ago - GlobeNewsWire

CNS Pharmaceuticals Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

Sites in France and Spain now open and actively enrolling Enrollment progressing with 26 clinical trial sites open to-date of the 59 sitesselected across the U.S., Italy, France, Spain, and Switzerlan...

4 months ago - PRNewsWire

CNS Pharmaceuticals to Present at the Virtual Investor Innovations in Oncology - Ongoing Pivotal Global Study for Treatment of Glioblastoma Multiforme (GBM)

Live moderated video webcast with Management to discuss potentially pivotal global study of lead asset, Berubicin, on Wednesday, September 28 th at 1:00 PM ET HOUSTON , Sept. 23, 2022 /PRNewswire/ -- ...

4 months ago - PRNewsWire

CNS Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

HOUSTON , Sept. 7, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc.  (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary ...

5 months ago - PRNewsWire

CNS Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Continued execution on clinical operations for potentially pivotal global trial evaluating Berubicin for the treatment of Glioblastoma Multiforme ("GBM")   Enrollment progressing with 23 clinical tria...

6 months ago - PRNewsWire

CNS Pharmaceuticals Urges Shareholders to Vote in Favor of Proxy Proposals for the Upcoming Annual Meeting of Shareholders on July 27, 2022

Company reiterates support of proposals for the authorization to increase number of shares available for issuance by the Company and authorization for the Board to effect a reverse stock split at thei...

7 months ago - PRNewsWire

CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

Expanded eligibility for patients who have received multiple therapies as first line therapy for GBM Company continues to enroll patients for the trial with 19 clinical trial sites open to-date, and a...

8 months ago - PRNewsWire

CNS Pharmaceuticals Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

HOUSTON , June 8, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary an...

8 months ago - PRNewsWire

CNS Pharmaceuticals Announces Presentation at the H.C. Wainwright Global Investment Conference

HOUSTON , May 24, 2022 /PRNewswire/ --  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary a...

9 months ago - PRNewsWire

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

HOUSTON , May 18, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary an...

9 months ago - PRNewsWire

CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Recent approvals of potentially pivotal Berubicin Study into Switzerland, France, and Spain expected to significantly drive patient enrollment Opportunities for Berubicin to be used in additional onco...

9 months ago - PRNewsWire

CNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Continued advancement of global patient enrollment with Switzerland, France, and Spain approvals received for pivotal study of Berubicin HOUSTON , April 28, 2022 /PRNewswire/ -- CNS Pharmaceuticals, I...

10 months ago - PRNewsWire

JTC Team Announces Continuation of its Virtual Investor Spotlight Series with NASDAQ: AEZS, NASDAQ: CNSP, and NASDAQ: AREC

- Live video webcast events on Thursday, April 14 at 10 AM ET, 11:30 AM ET and 1 PM ET - FRENCHTOWN, NJ / ACCESSWIRE / April 13, 2022 / JTC Team ("JTC"), a fully integrated corporate communications an...

Other symbols: AEZSAREC
10 months ago - Accesswire

CNS Pharmaceuticals to Participate in the Virtual Investor Glioblastoma Multiforme (GBM) Spotlight Event

Live video webcast with moderated fireside chat with members from the CNS Pharmaceuticals management team and featuring Key Opinion Leader, Samuel A. Goldlust, MD, on Thursday, April 14th at 11:30 AM ...

10 months ago - PRNewsWire